Revlimid

(lenalidomide)

ApprovedSmall molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Lenalidomide is used to treat certain types of cancer, including multiple myeloma (a blood cancer) and certain lymphomas, as well as a blood disorder called myelodysplastic syndrome where the bone marrow doesn't make enough healthy blood cells.[2] Revlimid is currently approved and in use across 100 indications[4].[1]

Revlimid is one of 1130 small molecule programs targeting Neuroblastoma. It is currently in Approved.

100

Indications

930

Total Trials

Active Trials

1,129

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

NeuroblastomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

PlasmacytomaTerminated

Mantle Cell LymphomaCompleted

TreatmentRecruiting

Central Nervous System NeoplasmApproved

Bladder TumorApproved

Plasma Cell NeoplasmApproved

Colorectal NeoplasmApproved

Liver CancerApproved

NeuroblastomaPhase 1

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

PlasmacytomaPhase 3

Terminated

Mantle Cell LymphomaPhase 3

Completed

TreatmentPhase 3

Recruiting

Central Nervous System NeoplasmApproved

Approved

Bladder TumorApproved

Approved

Plasma Cell NeoplasmApproved

Approved

Colorectal NeoplasmApproved

Approved

Liver CancerApproved

Approved

Showing 10 of 100 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

91 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Multiple Myeloma

NCT03729804

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT04974216

Q1 2027

Phase 2Not yet recruiting

Cognitive Impairment

NCT06177028

Phase 2Active, not recruiting

Multiple Myeloma

NCT04126200

Q2 2027

Phase 2Recruiting

Efficacy and Safety

NCT07187167

Phase 2Active, not recruiting

Multiple Myeloma

NCT02415413

Clinical

Trials by Indication[1]

Multiple Myeloma74 trials

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Not yet recruiting· Regeneron logo

Regeneron·Phase 2/3·NCT07428369·1,570 enrolled

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Completed·SSellas Life Sciences Group·Phase 1/2·NCT01827137·20 enrolled

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy

Withdrawn·TTiziana Marangon·Phase 2·NCT01501370

Show 71 more trials

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Completed·FFondazione EMN Italy Onlus·Phase 2·NCT01264315·53 enrolled

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05317416·811 enrolled

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01647165

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT01155583·45 enrolled

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Recruiting·—·Phase 2/3·NCT05665140·100 enrolled

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01440582·77 enrolled

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma

Completed·KKing's College Hospital NHS Trust·Phase 1/2·NCT00915408·32 enrolled

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 3·NCT01850524·705 enrolled

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02252172·737 enrolled

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01891643·23 enrolled

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT02891811·124 enrolled

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Active, not recruiting·UUniversity of Chicago·Phase 3·NCT02659293·180 enrolled

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·MMayo Clinic·Phase 1·NCT00687674·13 enrolled

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02874742·224 enrolled

Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

Completed·—·Phase 1·NCT02481934·5 enrolled

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00179647·1,913 enrolled

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT01091831·389 enrolled

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Terminated· Takeda logo

Takeda·Phase 1·NCT04272775·14 enrolled

Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma

Completed·UUniversity Hospital, Bordeaux·Phase 1·NCT01421927·13 enrolled

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed·MMichaela Liedtke·Phase 1/2·NCT01355705·14 enrolled

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Completed·UUniversity of Chicago·Phase 2·NCT02969837·46 enrolled

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1/2·NCT01383928·64 enrolled

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1/2·NCT01615029·45 enrolled

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01593410·194 enrolled

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01919086·30 enrolled

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

Completed·MMayo Clinic·Phase 2·NCT01706666·3 enrolled

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting·SSinocelltech Ltd.·Phase 3·NCT07297329·292 enrolled

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Completed· Sanofi logo

Sanofi·Phase 1·NCT02513186·90 enrolled

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT01109004·758 enrolled

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT00477750·33 enrolled

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Completed·—·Phase 2·NCT00378209·65 enrolled

Treatment Optimization in Patients With Untreated Multiple Myeloma

Terminated·DDr. med. Lars-Olof Muegge·Phase 2/3·NCT02145598·85 enrolled

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Suspended·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT06348147·39 enrolled

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01531998·14 enrolled

Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Withdrawn·KKaryopharm Therapeutics Inc·Phase 1/2·NCT02389543

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Completed· AbbVie logo

AbbVie·Phase 2·NCT00742560·101 enrolled

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Terminated·—·Phase 1/2·NCT01303965·14 enrolled

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Active, not recruiting·NNantes University Hospital·Phase 2·NCT06353022·103 enrolled

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02348528·65 enrolled

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03031730·35 enrolled

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03631043·30 enrolled

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 3·NCT01564537·722 enrolled

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00617591·57 enrolled

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Completed·MMayo Clinic·Phase 2·NCT01794039·9 enrolled

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Unknown status·SSun Yat-sen University·Phase 2·NCT03641456·50 enrolled

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

Active, not recruiting·UUniversity of Chicago·Phase 3·NCT03729804·250 enrolled

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Completed· Pfizer logo

Pfizer·Phase 1·NCT00525447·36 enrolled

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03290950·75 enrolled

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT03283046

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Completed·HHearn Jay Cho·Phase 1·NCT02655458·15 enrolled

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT02086552·28 enrolled

RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Completed·MMassachusetts General Hospital·Phase 1·NCT00729638·28 enrolled

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT03319667·475 enrolled

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1·NCT01965353·21 enrolled

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00478777·150 enrolled

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active, not recruiting· GSK logo

GSK·Phase 2·NCT04126200·208 enrolled

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Unknown status·KKeymed Biosciences Co.Ltd·Phase 1·NCT04818372·87 enrolled

"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "

Completed·VVejle Hospital·Phase 2/3·NCT02419118·4 enrolled

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Active, not recruiting·NNantes University Hospital·Phase 2·NCT03606577·50 enrolled

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00410605·39 enrolled

Lenalidomide Maintenance Therapy for Multiple Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01675141·11 enrolled

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT02415413·90 enrolled

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00729118·19 enrolled

ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

Completed·VVejle Hospital·Phase 2·NCT01481194·35 enrolled

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting·EEuropean Myeloma Network B.V.·Phase 3·NCT05243797·1,594 enrolled

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT02215980·210 enrolled

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02331368·32 enrolled

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02843074·53 enrolled

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 1·NCT00603447·84 enrolled

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

Recruiting·PPETHEMA Foundation·Phase 2·NCT07045909·30 enrolled

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00420849·587 enrolled

Lymphoma27 trials

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01755975·49 enrolled

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Terminated·—·Phase 1·NCT01116154·30 enrolled

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01955499·39 enrolled

Show 24 more trials

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Completed·UUniversity of Chicago·Phase 1/2·NCT02213913·55 enrolled

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00413036·217 enrolled

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Terminated·NNYU Langone Health·Phase 1/2·NCT02875067·6 enrolled

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06006117·260 enrolled

Maintenance Lenalidomide in Lymphoma

Completed·—·Phase 1/2·NCT01575860·8 enrolled

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05846750·59 enrolled

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Completed·MMayo Clinic·Phase 1/2·NCT01075321·58 enrolled

Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Terminated·UUniversity of California, Davis·Phase 2·NCT01316523·30 enrolled

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01995669·66 enrolled

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 1/2·NCT02561273·54 enrolled

Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas

Completed·UUniversity Hospital, Essen·Phase 1/2·NCT01788189·37 enrolled

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01145495·66 enrolled

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

Completed·UUniversity of Cologne·Phase 1·NCT01056679·30 enrolled

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

Completed·MMayo Clinic·Phase 2·NCT00784927·36 enrolled

Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Unknown status·RRuijin Hospital··NCT04435743·1,000 enrolled

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00179673·43 enrolled

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07030699·27 enrolled

Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00765245·44 enrolled

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Terminated·UUniversity of California, Davis·Phase 2·NCT00848328·30 enrolled

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT00704691·1 enrolled

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

Unknown status·PPuyang Oilfield General Hospital·Phase 2·NCT05014100·55 enrolled

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Completed·—·Phase 2·NCT00783367·50 enrolled

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03019640·22 enrolled

A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

Completed·AAHS Cancer Control Alberta·Phase 2·NCT00322985·40 enrolled

Chronic Lymphocytic Leukemia14 trials

Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)

Terminated·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 1/2·NCT01403246·9 enrolled

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Terminated·RRoswell Park Cancer Institute·N/A·NCT01649791·8 enrolled

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01351896·49 enrolled

Show 11 more trials

Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 1/2·NCT00727415·42 enrolled

Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

Completed·GGeorgetown University·Phase 2·NCT00860457·22 enrolled

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Terminated·TThomas Kipps·Phase 2·NCT01600053·11 enrolled

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Terminated·MMayo Clinic·Phase 1/2·NCT01003769·5 enrolled

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Completed· Gilead logo

Gilead·Phase 1·NCT01088048·241 enrolled

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00536341·64 enrolled

Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT00751296·27 enrolled

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02225275·9 enrolled

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00632359·33 enrolled

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00759603·60 enrolled

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

Completed·LLeslie Andritsos·Phase 1·NCT00466895·37 enrolled

Lenalidomide11 trials

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01349569·19 enrolled

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04423926·91 enrolled

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT02354313·300 enrolled

Show 8 more trials

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Terminated·AAntengene Corporation·Phase 1/2·NCT05265975·54 enrolled

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT

Completed·HHeinrich-Heine University, Duesseldorf·Phase 2·NCT02472691·50 enrolled

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03411031·18 enrolled

Evaluation of the Immune Restoration Potential Of Lenalidomide

Withdrawn·UUniversity of California, San Diego·Phase 2·NCT02371577

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06760156·28 enrolled

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Completed·WWeill Medical College of Cornell University·Phase 2·NCT01125176·15 enrolled

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Unknown status·—·Phase 3·NCT04084626·40 enrolled

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT03863184·37 enrolled

Myelodysplastic Syndrome7 trials

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01133275·28 enrolled

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Completed·UUniversity of California, Davis·Phase 1·NCT03359460·4 enrolled

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT00699842·8 enrolled

Show 4 more trials

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01029262·239 enrolled

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Completed·WWashington University School of Medicine·Phase 2·NCT01246076·24 enrolled

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00812968·11 enrolled

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Completed·UUniversity of California, Davis·Phase 1·NCT01433965·16 enrolled

39 more indications

Acute Myeloid Leukemia6 trials

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01358734·88 enrolled

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Terminated·—·Phase 1/2·NCT02038153·3 enrolled

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01246622·32 enrolled

Show 3 more trials

LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

Terminated·PPETHEMA Foundation·Phase 4·NCT01198054·4 enrolled

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·SStanford University·Phase 1·NCT01904643·17 enrolled

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02538965·17 enrolled

Follicular Lymphoma5 trials

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01644799·8 enrolled

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05371093·231 enrolled

Show 2 more trials

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01938001·358 enrolled

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02532257·48 enrolled

Myelodysplastic Syndromes5 trials

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

Completed·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 2·NCT01081431·91 enrolled

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Completed· Pfizer logo

Pfizer·Phase 1·NCT00502112·13 enrolled

A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07465029·1,300 enrolled

Show 2 more trials

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Terminated·TTechnische Universität Dresden·Phase 2·NCT00720850·10 enrolled

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00840827·6 enrolled

Diffuse Large B-Cell Lymphoma5 trials

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting·—·Phase 1/2·NCT02628405·30 enrolled

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00294632·54 enrolled

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT04544059·87 enrolled

Show 2 more trials

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT01197560·111 enrolled

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

Active, not recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT04974216·71 enrolled

Maintenance Therapy4 trials

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Recruiting·JJinling Hospital, China·Phase 2/3·NCT06324266·80 enrolled

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

Not yet recruiting·NNantes University Hospital·Phase 2·NCT06931704·176 enrolled

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Unknown status·GGe Zheng·Phase 3·NCT04490707·60 enrolled

Show 1 more trial

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02112175·46 enrolled

Mantle Cell Lymphoma3 trials

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01729104·18 enrolled

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06192888·39 enrolled

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05788289·4 enrolled

Dexamethasone3 trials

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT03795571·12 enrolled

Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone

Unknown status·KKosin University Gospel Hospital·Phase 2·NCT03809780·70 enrolled

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Active, not recruiting·—·Phase 2·NCT04653246·52 enrolled

Efficacy and Safety2 trials

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00737529·134 enrolled

Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease

Recruiting·—·Phase 2·NCT07187167·40 enrolled

Myelofibrosis2 trials

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00227591·48 enrolled

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01375140·31 enrolled

Prostate Cancer2 trials

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Terminated·UUniversity of Nebraska·Phase 1/2·NCT01093183·25 enrolled

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·—·Phase 2·NCT00460031·34 enrolled

AL amyloidosis2 trials

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Completed·SSeoul National University Hospital·Phase 3·NCT04298372·2 enrolled

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT00607581·21 enrolled

Ovarian Cancer1 trial

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

Completed·AARCAGY/ GINECO GROUP·Phase 1/2·NCT01111903·67 enrolled

Elderly Patients1 trial

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Unknown status·HHuiqiang Huang·Phase 1/2·NCT04796857·30 enrolled

Urothelial Carcinoma1 trial

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT01342172·9 enrolled

Neuropathy1 trial

Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study

Terminated·OOhio State University·Phase 1·NCT03701711·11 enrolled

Complex Regional Pain Syndrome1 trial

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00067743·40 enrolled

Metastatic Melanoma1 trial

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00412581·28 enrolled

Cognitive impairment1 trial

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

Not yet recruiting·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 2·NCT06177028·45 enrolled

Newly Diagnosed1 trial

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Active, not recruiting·UUniversity of Heidelberg Medical Center·Phase 3·NCT03617731·662 enrolled

Myelodysplasia1 trial

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

Completed·MMassachusetts General Hospital·Phase 1·NCT00580242·23 enrolled

Anemia1 trial

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Completed·—·Phase 2·NCT01772420·52 enrolled

Cancer Pain1 trial

Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00684242·4 enrolled

Primary Systemic Amyloidosis1 trial

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Completed·—·Phase 2·NCT00679367·16 enrolled

Transplantation1 trial

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Terminated·MMassachusetts General Hospital·Phase 1·NCT02255162·8 enrolled

Amyloidosis1 trial

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis

Completed·HHeidelberg University·Phase 2·NCT00883623·50 enrolled

Richter's Syndrome1 trial

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Completed·UUniversity of California, San Diego·Phase 1·NCT03113695·4 enrolled

Bladder Cancer1 trial

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01373294·17 enrolled

Maintenance Treatment1 trial

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Active, not recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2·NCT03104842·246 enrolled

Methylprednisolone1 trial

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01496976·45 enrolled

Stem Cell Transplant1 trial

Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01702831·78 enrolled

Treatment1 trial

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02719613·67 enrolled

Colorectal Cancer1 trial

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01032291·51 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01497496·29 enrolled

Safety and Efficacy1 trial

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Completed·MMorphoSys AG·Phase 2·NCT02399085·81 enrolled

Acute Leukemia1 trial

Phase I Study of Lenalidomide in Patients With Acute Leukemia

Terminated·MMehrdad Abedi, MD·Phase 1·NCT01615042·6 enrolled

Neuroblastoma1 trial

DNA Vaccination Against Neuroblastoma

Unknown status·—·Phase 1·NCT04049864·12 enrolled

CLL/SLL1 trial

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Terminated·—·Phase 1·NCT00543114·9 enrolled

Waldenstrom macroglobulinemia1 trial

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01779167·4 enrolled

Central Nervous System Lymphoma1 trial

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04129710·120 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 29, 2006

REVLIMID

NDA NDA021880

Feb 23, 2009

REVLIMID

NDA NDA021880

Feb 23, 2009

REVLIMID

NDA NDA021880

Feb 23, 2009

REVLIMID

NDA NDA021880

Aug 3, 2010

REVLIMID

NDA NDA021880

Oct 12, 2010

REVLIMID

NDA NDA021880

Dec 21, 2011

REVLIMID

NDA NDA021880

Dec 21, 2011

REVLIMID

NDA NDA021880

Mar 12, 2012

REVLIMID

NDA NDA021880

May 9, 2012

REVLIMID

NDA NDA021880

Feb 8, 2013

REVLIMID

NDA NDA021880

Feb 8, 2013

REVLIMID

NDA NDA021880

Jun 5, 2013

REVLIMID

NDA NDA021880

Nov 4, 2013

REVLIMID

NDA NDA021880

Nov 15, 2013

REVLIMID

NDA NDA021880

Dec 19, 2013

REVLIMID

NDA NDA021880

Sep 12, 2014

REVLIMID

NDA NDA021880

Sep 12, 2014

REVLIMID

NDA NDA021880

Feb 17, 2015

REVLIMID

NDA NDA021880

Sep 13, 2015

REVLIMID

NDA NDA021880

Oct 27, 2015

REVLIMID

NDA NDA021880

Dec 1, 2015

REVLIMID

NDA NDA021880

Apr 22, 2016

REVLIMID

NDA NDA021880

Feb 22, 2017

REVLIMID

NDA NDA021880

Jun 27, 2017

REVLIMID

NDA NDA021880

Sep 15, 2017

REVLIMID

NDA NDA021880

Nov 30, 2017

REVLIMID

NDA NDA021880

Nov 30, 2017

REVLIMID

NDA NDA021880

Dec 29, 2017

REVLIMID

NDA NDA021880

Jan 22, 2019

REVLIMID

NDA NDA021880

May 28, 2019

REVLIMID

NDA NDA021880

Oct 30, 2019

REVLIMID

NDA NDA021880

Sep 24, 2020

REVLIMID

NDA NDA021880

Aug 5, 2021

REVLIMID

NDA NDA021880

Aug 31, 2021

REVLIMID

NDA NDA021880

May 24, 2022

REVLIMID

NDA NDA021880

Mar 24, 2023

REVLIMID

NDA NDA021880

Apr 27, 2026

REVLIMID

NDA NDA021880

Jul 22, 2026

REVLIMID

NDA NDA021880

Sources

References

[1]
ClinicalTrials.gov — 930 trial records for lenalidomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Revlimid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — lenalidomide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for lenalidomide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021880). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Revlimid. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Modulator; CRL4(CRBN) E3 Ubiquitin Ligase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Patent Landscape[6]

Patent Cliff

Apr 27, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7465800Apr 27, 2027

8741929Mar 8, 2028

Revlimid

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Multiple Myeloma74 trials

Lymphoma27 trials

Chronic Lymphocytic Leukemia14 trials

Lenalidomide11 trials

Myelodysplastic Syndrome7 trials

Acute Myeloid Leukemia6 trials

Follicular Lymphoma5 trials

Myelodysplastic Syndromes5 trials

Diffuse Large B-Cell Lymphoma5 trials

Maintenance Therapy4 trials

Mantle Cell Lymphoma3 trials

Dexamethasone3 trials

Efficacy and Safety2 trials

Myelofibrosis2 trials

Prostate Cancer2 trials

AL amyloidosis2 trials

Ovarian Cancer1 trial

Elderly Patients1 trial

Urothelial Carcinoma1 trial

Neuropathy1 trial

Complex Regional Pain Syndrome1 trial

Metastatic Melanoma1 trial

Cognitive impairment1 trial

Newly Diagnosed1 trial

Myelodysplasia1 trial

Anemia1 trial

Cancer Pain1 trial

Primary Systemic Amyloidosis1 trial

Transplantation1 trial

Amyloidosis1 trial

Richter's Syndrome1 trial

Bladder Cancer1 trial

Maintenance Treatment1 trial

Methylprednisolone1 trial

Stem Cell Transplant1 trial

Treatment1 trial

Colorectal Cancer1 trial

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Safety and Efficacy1 trial

Acute Leukemia1 trial

Neuroblastoma1 trial

CLL/SLL1 trial

Waldenstrom macroglobulinemia1 trial

Central Nervous System Lymphoma1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News